Advertisement
Surgical Pathology Clinics

Cribriform Lesions of the Prostate Gland

Published:October 12, 2022DOI:https://doi.org/10.1016/j.path.2022.07.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgical Pathology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Epstein J.I.
        • Egevad L.
        • Amin M.B.
        • et al.
        The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system.
        Am J Surg Pathol. 2016; 40: 244-252
        • Chen Z.
        • Pham H.
        • Abreu A.
        • et al.
        Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason Score 7 prostate cancer with Cribriform Gleason Pattern 4.
        Hum Pathol. 2021; https://doi.org/10.1016/j.humpath.2021.09.005
        • Hollemans E.
        • Verhoef E.I.
        • Bangma C.H.
        • et al.
        Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
        Mod Pathol. 2019; 32: 139-146
        • Keefe D.T.
        • Schieda N.
        • El Hallani S.
        • et al.
        Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
        Virchows Arch. 2015; 467: 437-442
        • Kweldam C.F.
        • Kummerlin I.P.
        • Nieboer D.
        • et al.
        Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
        Mod Pathol. 2016; 29: 630-636
        • Kweldam C.F.
        • Wildhagen M.F.
        • Steyerberg E.W.
        • et al.
        Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.
        Mod Pathol. 2015; 28: 457-464
        • Kweldam C.F.
        • Kummerlin I.P.
        • Nieboer D.
        • et al.
        Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.
        Eur J Cancer. 2016; 66: 26-33
        • Hollemans E.
        • Verhoef E.I.
        • Bangma C.H.
        • et al.
        Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients.
        Mod Pathol. 2021; 34: 184-193
        • van Leenders G.
        • Kweldam C.F.
        • Hollemans E.
        • et al.
        Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups.
        Eur Urol. 2020; 77: 191-198
        • Epstein J.I.
        • Amin M.B.
        • Fine S.W.
        • et al.
        The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer.
        Arch Pathol Lab Med. 2021; 145: 461-493
        • van Leenders G.
        • van der Kwast T.H.
        • Grignon D.J.
        • et al.
        The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma.
        Am J Surg Pathol. 2020; 44: e87-e99
        • Flood T.A.
        • Schieda N.
        • Keefe D.T.
        • et al.
        Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
        Virchows Arch. 2016; 469: 313-319
        • Kweldam C.F.
        • Nieboer D.
        • Algaba F.
        • et al.
        Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists.
        Histopathology. 2016; 69: 441-449
        • Shah R.B.
        • Cai Q.
        • Aron M.
        • et al.
        Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations.
        Am J Cancer Res. 2021; 11: 3990-4001
        • van der Slot M.A.
        • Hollemans E.
        • den Bakker M.A.
        • et al.
        Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.
        Virchows Arch. 2021; 478: 249-256
        • Iczkowski K.A.
        • van Leenders G.
        • Tarima S.
        • et al.
        Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts.
        Ann Diagn Pathol. 2021; 52: 151733
        • van der Kwast T.H.
        • van Leenders G.J.
        • Berney D.M.
        • et al.
        ISUP consensus definition of cribriform pattern prostate cancer.
        Am J Surg Pathol. 2021; 45: 1118-1126
        • Iczkowski K.A.
        • Torkko K.C.
        • Kotnis G.R.
        • et al.
        Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.
        Am J Clin Pathol. 2011; 136: 98-107
        • Kovi J.
        • Jackson M.A.
        • Heshmat M.Y.
        Ductal spread in prostatic carcinoma.
        Cancer. 1985; 56: 1566-1573
        • Moch H.
        • Humphrey P.A.
        • Ulbright T.M.
        • et al.
        WHO classification of tumours of the urinary system and male genital organs.
        4th ed. International Agency for Research on Cancer, Lyon CEDEX, France2016
        • Khani F.
        • Epstein J.I.
        Prostate biopsy specimens with Gleason 3+3=6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes.
        Am J Surg Pathol. 2015; 39: 1383-1389
        • Miyai K.
        • Divatia M.K.
        • Shen S.S.
        • et al.
        Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
        Int J Clin Exp Pathol. 2014; 7: 2518-2526
        • Robinson B.D.
        • Epstein J.I.
        Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings.
        J Urol. 2010; 184: 1328-1333
        • Khani F.
        • Wobker S.E.
        • Hicks J.L.
        • et al.
        Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
        J Pathol. 2019; 249: 79-89
        • Varma M.
        Intraductal carcinoma of the prostate: a guide for the practicing pathologist.
        Adv Anat Pathol. 2021; 28: 276-287
        • Varma M.
        • Epstein J.I.
        Head to head: should the intraductal component of invasive prostate cancer be graded?.
        Histopathology. 2021; 78: 231-239
        • Kato M.
        • Tsuzuki T.
        • Kimura K.
        • et al.
        The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.
        Mod Pathol. 2016; 29: 166-173
        • Kimura K.
        • Tsuzuki T.
        • Kato M.
        • et al.
        Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
        Prostate. 2014; 74: 680-687
        • Cohen R.J.
        • Wheeler T.M.
        • Bonkhoff H.
        • et al.
        A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
        Arch Pathol Lab Med. 2007; 131: 1103-1109
        • Guo C.C.
        • Epstein J.I.
        Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance.
        Mod Pathol. 2006; 19: 1528-1535
        • Shah R.B.
        • Magi-Galluzzi C.
        • Han B.
        • et al.
        Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
        Am J Surg Pathol. 2010; 34: 470-477
        • Samaratunga H.
        • Delahunt B.
        • Egevad L.
        • et al.
        Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded.
        Pathology. 2020; 52: 192-196
        • Varma M.
        • Egevad L.
        • Delahunt B.
        • et al.
        Reporting intraductal carcinoma of the prostate: a plea for greater standardization.
        Histopathology. 2017; 70: 504-507
        • Fine S.W.
        • Al-Ahmadie H.A.
        • Chen Y.B.
        • et al.
        Comedonecrosis revisited: strong association with intraductal carcinoma of the prostate.
        Am J Surg Pathol. 2018; 42: 1036-1041
        • Madan R.
        • Deebajah M.
        • Alanee S.
        • et al.
        Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria.
        Histopathology. 2019; 74: 1081-1087
        • Magers M.
        • Kunju L.P.
        • Wu A.
        Intraductal carcinoma of the prostate: morphologic features, differential diagnoses, significance, and reporting practices.
        Arch Pathol Lab Med. 2015; 139: 1234-1241
        • Kato M.
        • Hirakawa A.
        • Kobayashi Y.
        • et al.
        Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients.
        Mod Pathol. 2019; 32: 122-127
        • Saeter T.
        • Vlatkovic L.
        • Waaler G.
        • et al.
        Intraductal carcinoma of the prostate on diagnostic needle biopsy predicts prostate cancer mortality: a population-based study.
        Prostate. 2017; 77: 859-865
        • Miyai K.
        • Divatia M.K.
        • Shen S.S.
        • et al.
        Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
        Hum Pathol. 2014; 45: 1572-1581
        • Rijstenberg L.L.
        • Hansum T.
        • Hollemans E.
        • et al.
        Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.
        Histopathology. 2020; 77: 742-748
        • Chen-Maxwell D.
        • Prendeville S.
        Grading of prostate cancer: the impact of including intraductal carcinoma on the overall Grade Group assigned in diagnostic biopsies.
        Histopathology. 2020; 77: 503-507
        • Truong M.
        • Hollenberg G.
        • Weinberg E.
        • et al.
        Impact of gleason subtype on prostate cancer detection using multiparametric magnetic resonance imaging: correlation with final histopathology.
        J Urol. 2017; 198: 316-321
        • Harmon S.A.
        • Brown G.T.
        • Sanford T.
        • et al.
        Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging.
        Quant Imaging Med Surg. 2020; 10: 326-339
        • Tonttila P.P.
        • Ahtikoski A.
        • Kuisma M.
        • et al.
        Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer.
        BJU Int. 2019; 124: 992-998
        • Prendeville S.
        • Gertner M.
        • Maganti M.
        • et al.
        Role of magnetic resonance imaging targeted biopsy in detection of prostate cancer harboring adverse pathological features of intraductal carcinoma and invasive cribriform carcinoma.
        J Urol. 2018; 200: 104-113
        • Currin S.
        • Flood T.A.
        • Krishna S.
        • et al.
        Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
        J Magn Reson Imaging. 2019; 50: 279-287
        • Amin A.
        Prostate Ductal Adenocarcinoma.
        Appl Immunohistochem Mol Morphol. 2018; 26: 514-521
        • Hickman R.A.
        • Yu H.
        • Li J.
        • et al.
        Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate.
        Am J Surg Pathol. 2017; 41: 550-556
        • Shah R.B.
        • Nguyen J.K.
        • Przybycin C.G.
        • et al.
        Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
        Histopathology. 2019; 75: 346-353
        • Han B.
        • Suleman K.
        • Wang L.
        • et al.
        ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.
        Am J Surg Pathol. 2010; 34: 478-485
        • Shah R.B.
        • Yoon J.
        • Liu G.
        • et al.
        Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
        Histopathology. 2017; 71: 693-702https://doi.org/10.1111/his.13273
        • Bottcher R.
        • Kweldam C.F.
        • Livingstone J.
        • et al.
        Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
        BMC Cancer. 2018; 18: 8
        • Elfandy H.
        • Armenia J.
        • Pederzoli F.
        • et al.
        Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate.
        Mol Cancer Res. 2019; 17: 446-456
        • Lozano R.
        • Salles D.C.
        • Sandhu S.
        • et al.
        Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
        Eur J Cancer. 2021; 147: 74-83
        • Chua M.L.K.
        • Lo W.
        • Pintilie M.
        • et al.
        A prostate cancer "nimbosus": genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies.
        Eur Urol. 2017; 72: 665-674
        • Shah R.B.
        • Shore K.T.
        • Yoon J.
        • et al.
        PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
        Prostate. 2019; 79: 1267-1273
        • Lotan T.L.
        • Gumuskaya B.
        • Rahimi H.
        • et al.
        Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.
        Mod Pathol. 2013; 26: 587-603
        • Dawkins H.J.
        • Sellner L.N.
        • Turbett G.R.
        • et al.
        Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.
        Prostate. 2000; 44: 265-270
        • Bettendorf O.
        • Schmidt H.
        • Staebler A.
        • et al.
        Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.
        Genes Chromosomes Cancer. 2008; 47: 565-572